Executive summary: US Drug Patent 7,056,893 claims a water-based azalide antibiotic (e.g., azithromycin) formulation stabilized with a polymeric suspending agent defined as a water-swellable, water-insoluble crosslinked carboxy-vinyl polymer (at least 90% acrylic acid monomers; 0.1% to 5.0% difunctional crosslinker) and set at a narrow pH window ~6.0 to 6.6. Claim scope is anchored in (i) ophthalmic aqueous formulations, (ii) depot/sustained-release constructs delivering drug concentrations above MIC50 for at least ~12 hours, and (iii) a manufacturing method that forms the formulation by forming an acidic dispersion/solution (pH <5), then adding base and water to reach pH 6.0 to 6.6. The estate is framed as a formulation + process + treatment-method bundle, with downstream freedom-to-operate largely determined by whether a competitor uses a functionally similar polymer/suspending system and hits the same pH and concentration windows, including depot retention and viscosity/pH-trigger behavior.

US Patent 7,056,893 (Azalide Antibiotic Ophthalmic Depot Formulations): Claim Scope, Validity Angles, and US Patent Landscape

What exactly do the claims cover in US 7,056,893? (composition pH window + polymer + depot)

Core claim architecture: The patent is written as a stacked, limiting set of features. Independent coverage is built around three elements that recur through dependent claims:

Aqueous composition with:
- water
- an azalide antibiotic (explicitly includes azithromycin in dependent claims)
- a polymeric suspending agent
Narrow pH: about 6.0 to 6.6 (with multiple narrower bands claimed)
Specific polymer definition when you narrow further: a water-swellable, water-insoluble crosslinked carboxy-vinyl polymer with:
- ≥90% acrylic acid monomers
- ~0.1% to ~5.0% difunctional crosslinking agent
- polymer present at ~0.5% to ~1.2% (in the dependent chain)

How broad is Claim 1 versus downstream limitations?

Claim 1 is the broadest: it does not require ophthalmic, depot, azithromycin-specific chemistry (except via dependent claims), nor the exact polymer monomer/crosslinker composition.
Claims 2–4 add ophthalmic + polymer specificity.
Claims 5–6 add depot format + sustained drug above MIC50 for at least ~12 hours.
Claims 7–12 fix the azalide as azithromycin and include additional pH subranges (6.2–6.4; 6.3).

Practical reading: In infringement and licensing terms, the case turns on whether the accused product matches (a) the pH, and (b) the suspending polymer identity/function as defined when those dependent claims are asserted.

What are the key dependent claim “fences” that competitors must avoid?

Ophthalmic formulation fence (Claim 2)

Claim 2 limits Claim 1 to an ophthalmic composition.
If a product is nasal/otic/systemic rather than ophthalmic, this dependent chain is typically inapplicable.

Polymer identity fence (Claims 3–4 and repeated later)

Claim 3: polymer must be water-swellable water-insoluble crosslinked carboxy-vinyl polymer.
Claim 4: polymer must have:

≥90% acrylic acid monomers
~0.1% to ~5.0% difunctional crosslinker
polymer amount ~0.5% to ~1.2% in the formulation

Depot/sustained-release fence (Claims 5–6 and method Claim 21, Claim 31)

Claim 5: composition “incorporated into a formulation administerable in a depot format.”
Claim 6: depot contains enough azithromycin to maintain above MIC50 for ≥ about 12 hours.

Practical reading: Shortening release to less than 12 hours, or demonstrating MIC exposure below that threshold, is a direct design-around lever, assuming other features remain contested.

Azithromycin-specific fence (Claims 7, 8, 32–33)

Claim 7 specifies azithromycin.
Claim 8 includes a chemical formula with substituent definition (R1 and R2 each hydrogen or methyl).
Method claims similarly recite azithromycin.

Concentration and pH subrange fences (Claims 9–12, 10–12, 38)

Claim 9: azalide antibiotic concentration ~0.1% to ~10.0%
Claim 10: pH ~6.0 to ~6.5
Claims 11–12: pH narrower ~6.2 to ~6.4, or ~6.3
Claim 38: azithromycin concentration ~0.1% to ~0.5%
Claims 10–12 and 24–26, 40–44 provide dose-duration variants that can matter if a competitor’s regimen is similar.

What additional coverage exists beyond simple composition claims? (multi-agent formulations + expanded medicament list)

Claim 13 broadens by allowing additional agents:

buffering agent, osmolarity adjusting agent, disodium EDTA
the same polymer suspending system
an “additional medicament” selected from antibiotic, antiviral, antifungal, anesthetic, anti-inflammatory, anti-allergic

Claim 14 gives an explicit exemplified list of additional medicaments (aminoglycosides, fluoroquinolones, sulfonamides, topical antiseptics/antibiotics, antifungals, corticosteroids, NSAIDs, antihistamines, etc.).

Claim 37 further expands what can be present in Claim 1:

solubilizing agent, buffering, osmolarity adjustment, chelating (disodium EDTA)
plus polymer suspending agent
plus additional medicament list again (antibiotic/antiviral/antifungal/anesthetic/anti-inflammatory/anti-allergic)

Practical reading: The patent is not limited to “polymer + drug + water.” The claims anticipate combination products and may complicate design-around where an ophthalmic combo includes a polymer system and pH window.

What formulations are covered for solid/semi-solid/powder/lyophilized products? (Claim 15–16)

Claim 15 covers dry or reconstitutable forms:

“solid, semi-solid, powdered, or lyophilized composition”
containing azalide antibiotic + polymeric suspending agent
that produces an aqueous formulation with pH ~6.0 to ~6.6 upon addition of water.

Claim 16 narrows polymer to “lightly crosslinked carboxy vinyl polymer.”

Practical reading: If a competitor sells a powder kit with reconstitution to the claimed pH and polymer profile, the patent can reach even if the liquid formulation is prepared by the end user or clinical setting.

What is the covered manufacturing process, and how specific is it? (Claim 17–22)

Claim 17 is a multi-step method:

(a) disperse/solubilize azalide + polymer in aqueous medium at pH < about 5.0
(b) add base
(c) add water
(d) adjust to pH ~6.0 to ~6.6

Claim 18 specifies example buffer: citric acid buffer or solution; base is sodium citrate.

Claim 19 specifies pH adjustment by adding sodium hydroxide in step (b) or (d).

Claim 20 ties to ocular depot-like behavior:

polymer definition as in Claim 4
pH ~6.2 to ~6.4
viscosity increases when composition pH rises to at least ~7.0 upon administration to a target tissue.

Claim 21 ties method to depot sustained release:

ocular depot
sufficient azithromycin to sustain release for ≥ about 12 hours.

Claim 22 adds osmolarity adjustment step.

Practical reading: This method claim can be asserted in process infringement settings where the accused manufacturer makes a composition by the same acid-to-neutral pH ramp with the same polymer system. If a competitor uses a different polymer treatment or forms pH by a different sequence not matching the claim steps, litigation focus shifts to whether steps are met literally or equivalently.

What treatment method does the patent claim? (Claims 23–44, incl. dose and duration)

Claim 23: Treat bacterial infection by administering azalide + polymeric suspending agent composition at antibacterial effective amount, pH 6.0 to 6.6.

Claim 27: Treat bacterial infection by administering to the eye; pH 6.0 to 6.6.

Claims 28–31:

injected into eye (Claim 28)
topically applied to eye (Claim 29)
depot format with sustained release ≥12 hours (Claim 31)
azithromycin-specific (Claims 32, 33)

Dose regimen subclaims:

Claims 39–41: 1–2 doses/day for:
- 1–3 days (39)
- ≥6 days (40)
- 6–14 days (41)
Claims 42–44 mirror those regimen ranges for ocular treatment (1–3 days; ≥6 days; 6–14 days).

Practical reading: For a competitor, the regimen and route matter if litigation asserts treatment-method claims. For generics, method-of-use patents can be harder to “design around” because clinicians choose dosing consistent with the label or off-label use.

How can competitors design around US 7,056,893?

pH design-around

Avoid pH ~6.0 to 6.6.
The tightest subbands (6.2–6.4 and 6.3) provide further options.

Polymer design-around

Replace the “water-swellable, water-insoluble crosslinked carboxy-vinyl polymer” defined by:
- ≥90% acrylic acid monomers
- 0.1% to 5.0% difunctional crosslinker
- polymer content ~0.5% to ~1.2%
Use a different suspending mechanism (e.g., non-carboxy-vinyl crosslinked polymers, HPMC/CMC systems with different swellability/insolubility behavior, or particulate suspensions without the defined polymer parameters).

Depot/sustained-release design-around

Make depot release shorter than ~12 hours or avoid maintaining concentration above MIC50 for that duration.

Route and indication strategy

If the patent is asserted narrowly on ocular delivery, route changes (where label supports it) can reduce exposure, though that does not typically avoid all claims because the independent Claim 1 is not ophthalmic and the method claims can still be asserted with different delivery routes.

What patent estate is likely implicated beyond US 7,056,893? (how this claim set maps to common families)

US 7,056,893 is a formulation-centric patent that usually arises from a family with:

drug-formulation dependents (pH window, polymer composition, polymer content)
reconstitution/dry form dependents
method of manufacture dependents (acid solubilization then neutralization)
depot/sustained-release or viscosity-trigger dependents
treatment method dependents (eye, topical/injection, dosing regimen)

Scope linkage: the claim text is dense and repetitive across composition, method of preparation, and method of treatment. That pattern is consistent with an estate built for multi-assertion leverage: composition for product infringement, process for manufacturing infringement, and use for clinician/label scenarios.

Business implication: in negotiations, the “core licensing unit” tends to be the polymer system + pH + sustained-release performance for the depot ophthalmic context.

What is the Orange Book status of US 7,056,893, and how does it affect generic entry risk?

Cannot be provided from the information supplied. The requested analysis requires the specific FDA application (NDA/BLA/ANDA), listed active ingredient(s), dosage form, and Orange Book patent listing entries tied to US 7,056,893. Without that mapping, an Orange Book exclusivity and Paragraph IV entry-risk assessment cannot be produced accurately.

When does US 7,056,893 lose exclusivity? (expiration and enforcement timeline)

Cannot be provided from the information supplied. A defensible exclusivity timeline requires the patent’s:

filing date and priority chain
prosecution history affecting term adjustments
maintenance fee status
any terminal disclaimers or patent term adjustments
related exclusivity periods for the underlying FDA application

What patent litigation typically arises with composition and method-of-use claims like these?

Cannot be provided without the litigation docket history for US 7,056,893 and its family members, including:

case captions and jurisdictions
asserted claims
settlement terms (noninfringement, licenses, carveouts, launch delays)
FDA timing tied to ANDA/BLA challenges

How strong is the claim set legally? (claim construction pressure points)

Even without file-history, the claim text points to specific strength and vulnerability themes.

Strength points

Specific parameterization: pH ranges, polymer monomer fraction, crosslinker range, polymer loading, and depot MIC50 time window create objective boundaries.
Multiple claim types: composition + method of preparation + treatment method increases assertion surface.
Depot performance threshold: “above MIC50 for at least about 12 hours” can anchor functional proof, not just formulation appearance.

Vulnerability points

Scope dependence on polymer definition: if an accused product uses a different polymer system, infringement can fall away quickly on dependent claims (3–4).
Functional performance proof: depot MIC50 duration claims can become evidentiary battlegrounds (how MIC50 is determined for a given organism, test strain, and in vivo correlate).
Method-of-use route/dosing: if clinical practice or labeling deviates, treatment method subclaims may be harder to assert.

Claim-by-claim map: what each independent/dependent block covers

Composition block

Claim 1: water + polymeric suspending agent + azalide antibiotic; pH 6.0–6.6
Claim 2: ophthalmic
Claim 3–4: defined water-swellable, water-insoluble crosslinked carboxy-vinyl polymer with specified monomer/crosslinker and polymer load
Claim 5–6: depot + MIC50 above for ≥12 hours
Claims 7–8: azalide = azithromycin and formula constraints
Claims 9–12: azithromycin concentration and narrower pH bands (6.0–6.5, 6.2–6.4, 6.3)
Claims 13–14: multi-agent composition with buffering/osmolarity/EDTA and extensive “additional medicament” list
Claims 15–16: dry/reconstitutable products yielding aqueous pH 6.0–6.6
Claims 37–38: additional agents list and azithromycin concentration band (0.1–0.5%)

Manufacturing block

Claims 17–19: acid dispersion/solubilization (pH<5) then base addition then water addition then neutralization to pH 6.0–6.6
Claim 20: ocular viscosity increase on pH rise to ≥7.0
Claim 21–22: depot sustained-release (≥12 hours) and optional osmolarity adjustment

Treatment block

Claims 23–26: bacterial infection treatment generally at pH 6.0–6.6 with regimen subranges
Claims 27–33: ocular route, injection/topical; depot sustained release; azithromycin-specific
Claims 34–35: osmolarity agent and additional medicaments
Claims 39–44: dosing regimen timing ranges for general and ocular treatments

Key Takeaways

US 7,056,893 is built around a tight formulation triangle: pH ~6.0–6.6, azalide antibiotic (often azithromycin), and a defined crosslinked carboxy-vinyl polymer suspending system.
Ophthalmic and depot coverage are present through dependent claims; depot includes a performance threshold of sustained exposure above MIC50 for ≥~12 hours.
The estate includes composition, manufacturing method, and treatment method claims, which can widen enforcement reach across product manufacture, formulation preparation, and clinician use patterns.
For freedom-to-operate, the highest-risk overlaps are matching the pH window, using a polymer system meeting the acrylic acid monomer and crosslinker specifications, and achieving the depot sustained release duration/performance.

FAQs

Do the claims require azithromycin specifically, or do they cover other azalides?
The broad composition claims cover “azalide antibiotic,” while azithromycin is explicitly required in dependent claims (e.g., Claims 7, 32–33).
Is the patent limited to ophthalmic use only?
No. Ophthalmic treatment/compositions are covered via dependent claims, but the broad composition claim itself is not limited to ophthalmic use.
Can a dry powder product avoid the patent if it’s reconstituted in clinic?
No. The patent includes solid/powder/lyophilized compositions that yield the claimed aqueous pH 6.0–6.6 upon water addition (Claim 15).
What is the most direct design-around lever: pH or polymer?
Either can work depending on infringement theory, but dependent claims (polymer specificity) make the polymer profile a major gate, while the repeated pH limitations create a clear numerical fence.
How do the depot and MIC50 limitations affect infringement risk?
They shift the dispute toward measurable sustained-release performance, including how long drug levels remain above MIC50 for relevant organisms under the conditions tested.

References (APA)

United States Patent No. 7,056,893. (Patent claims text provided in prompt).

Title:	Topical treatment for prevention of ocular infections
Abstract:	Azalide antibiotics such as azithromycin are useful in the treatment and prevention of infections by bacteria and other parasites. Stabilized aqueous compositions containing azithromycin suitable for administration without reconstitution are provided for. Also provided for are aqueous formulations suitable for ocular administration in a employing a convenient dosing formulation suitable for administration in depot formats.
Inventor(s):	Samir Roy, Lyle M. Bowman
Assignee:	Sun Pharmaceutical Industries Inc
Application Number:	US10/160,060
Patent Claim Types: see list of patent claims	Use; Composition; Formulation;
Patent landscape, scope, and claims:	Executive summary: US Drug Patent 7,056,893 claims a water-based azalide antibiotic (e.g., azithromycin) formulation stabilized with a polymeric suspending agent defined as a water-swellable, water-insoluble crosslinked carboxy-vinyl polymer (at least 90% acrylic acid monomers; 0.1% to 5.0% difunctional crosslinker) and set at a narrow pH window ~6.0 to 6.6. Claim scope is anchored in (i) ophthalmic aqueous formulations, (ii) depot/sustained-release constructs delivering drug concentrations above MIC50 for at least ~12 hours, and (iii) a manufacturing method that forms the formulation by forming an acidic dispersion/solution (pH <5), then adding base and water to reach pH 6.0 to 6.6. The estate is framed as a formulation + process + treatment-method bundle, with downstream freedom-to-operate largely determined by whether a competitor uses a functionally similar polymer/suspending system and hits the same pH and concentration windows, including depot retention and viscosity/pH-trigger behavior. US Patent 7,056,893 (Azalide Antibiotic Ophthalmic Depot Formulations): Claim Scope, Validity Angles, and US Patent Landscape What exactly do the claims cover in US 7,056,893? (composition pH window + polymer + depot) Core claim architecture: The patent is written as a stacked, limiting set of features. Independent coverage is built around three elements that recur through dependent claims: Aqueous composition with: water an azalide antibiotic (explicitly includes azithromycin in dependent claims) a polymeric suspending agent Narrow pH: about 6.0 to 6.6 (with multiple narrower bands claimed) Specific polymer definition when you narrow further: a water-swellable, water-insoluble crosslinked carboxy-vinyl polymer with: ≥90% acrylic acid monomers ~0.1% to ~5.0% difunctional crosslinking agent polymer present at ~0.5% to ~1.2% (in the dependent chain) How broad is Claim 1 versus downstream limitations? Claim 1 is the broadest: it does not require ophthalmic, depot, azithromycin-specific chemistry (except via dependent claims), nor the exact polymer monomer/crosslinker composition. Claims 2–4 add ophthalmic + polymer specificity. Claims 5–6 add depot format + sustained drug above MIC50 for at least ~12 hours. Claims 7–12 fix the azalide as azithromycin and include additional pH subranges (6.2–6.4; 6.3). Practical reading: In infringement and licensing terms, the case turns on whether the accused product matches (a) the pH, and (b) the suspending polymer identity/function as defined when those dependent claims are asserted. What are the key dependent claim “fences” that competitors must avoid? Ophthalmic formulation fence (Claim 2) Claim 2 limits Claim 1 to an ophthalmic composition. If a product is nasal/otic/systemic rather than ophthalmic, this dependent chain is typically inapplicable. Polymer identity fence (Claims 3–4 and repeated later) Claim 3: polymer must be water-swellable water-insoluble crosslinked carboxy-vinyl polymer. Claim 4: polymer must have: ≥90% acrylic acid monomers ~0.1% to ~5.0% difunctional crosslinker polymer amount ~0.5% to ~1.2% in the formulation Depot/sustained-release fence (Claims 5–6 and method Claim 21, Claim 31) Claim 5: composition “incorporated into a formulation administerable in a depot format.” Claim 6: depot contains enough azithromycin to maintain above MIC50 for ≥ about 12 hours. Practical reading: Shortening release to less than 12 hours, or demonstrating MIC exposure below that threshold, is a direct design-around lever, assuming other features remain contested. Azithromycin-specific fence (Claims 7, 8, 32–33) Claim 7 specifies azithromycin. Claim 8 includes a chemical formula with substituent definition (R1 and R2 each hydrogen or methyl). Method claims similarly recite azithromycin. Concentration and pH subrange fences (Claims 9–12, 10–12, 38) Claim 9: azalide antibiotic concentration ~0.1% to ~10.0% Claim 10: pH ~6.0 to ~6.5 Claims 11–12: pH narrower ~6.2 to ~6.4, or ~6.3 Claim 38: azithromycin concentration ~0.1% to ~0.5% Claims 10–12 and 24–26, 40–44 provide dose-duration variants that can matter if a competitor’s regimen is similar. What additional coverage exists beyond simple composition claims? (multi-agent formulations + expanded medicament list) Claim 13 broadens by allowing additional agents: buffering agent, osmolarity adjusting agent, disodium EDTA the same polymer suspending system an “additional medicament” selected from antibiotic, antiviral, antifungal, anesthetic, anti-inflammatory, anti-allergic Claim 14 gives an explicit exemplified list of additional medicaments (aminoglycosides, fluoroquinolones, sulfonamides, topical antiseptics/antibiotics, antifungals, corticosteroids, NSAIDs, antihistamines, etc.). Claim 37 further expands what can be present in Claim 1: solubilizing agent, buffering, osmolarity adjustment, chelating (disodium EDTA) plus polymer suspending agent plus additional medicament list again (antibiotic/antiviral/antifungal/anesthetic/anti-inflammatory/anti-allergic) Practical reading: The patent is not limited to “polymer + drug + water.” The claims anticipate combination products and may complicate design-around where an ophthalmic combo includes a polymer system and pH window. What formulations are covered for solid/semi-solid/powder/lyophilized products? (Claim 15–16) Claim 15 covers dry or reconstitutable forms: “solid, semi-solid, powdered, or lyophilized composition” containing azalide antibiotic + polymeric suspending agent that produces an aqueous formulation with pH ~6.0 to ~6.6 upon addition of water. Claim 16 narrows polymer to “lightly crosslinked carboxy vinyl polymer.” Practical reading: If a competitor sells a powder kit with reconstitution to the claimed pH and polymer profile, the patent can reach even if the liquid formulation is prepared by the end user or clinical setting. What is the covered manufacturing process, and how specific is it? (Claim 17–22) Claim 17 is a multi-step method: (a) disperse/solubilize azalide + polymer in aqueous medium at pH < about 5.0 (b) add base (c) add water (d) adjust to pH ~6.0 to ~6.6 Claim 18 specifies example buffer: citric acid buffer or solution; base is sodium citrate. Claim 19 specifies pH adjustment by adding sodium hydroxide in step (b) or (d). Claim 20 ties to ocular depot-like behavior: polymer definition as in Claim 4 pH ~6.2 to ~6.4 viscosity increases when composition pH rises to at least ~7.0 upon administration to a target tissue. Claim 21 ties method to depot sustained release: ocular depot sufficient azithromycin to sustain release for ≥ about 12 hours. Claim 22 adds osmolarity adjustment step. Practical reading: This method claim can be asserted in process infringement settings where the accused manufacturer makes a composition by the same acid-to-neutral pH ramp with the same polymer system. If a competitor uses a different polymer treatment or forms pH by a different sequence not matching the claim steps, litigation focus shifts to whether steps are met literally or equivalently. What treatment method does the patent claim? (Claims 23–44, incl. dose and duration) Claim 23: Treat bacterial infection by administering azalide + polymeric suspending agent composition at antibacterial effective amount, pH 6.0 to 6.6. Claim 27: Treat bacterial infection by administering to the eye; pH 6.0 to 6.6. Claims 28–31: injected into eye (Claim 28) topically applied to eye (Claim 29) depot format with sustained release ≥12 hours (Claim 31) azithromycin-specific (Claims 32, 33) Dose regimen subclaims: Claims 39–41: 1–2 doses/day for: 1–3 days (39) ≥6 days (40) 6–14 days (41) Claims 42–44 mirror those regimen ranges for ocular treatment (1–3 days; ≥6 days; 6–14 days). Practical reading: For a competitor, the regimen and route matter if litigation asserts treatment-method claims. For generics, method-of-use patents can be harder to “design around” because clinicians choose dosing consistent with the label or off-label use. How can competitors design around US 7,056,893? pH design-around Avoid pH ~6.0 to 6.6. The tightest subbands (6.2–6.4 and 6.3) provide further options. Polymer design-around Replace the “water-swellable, water-insoluble crosslinked carboxy-vinyl polymer” defined by: ≥90% acrylic acid monomers 0.1% to 5.0% difunctional crosslinker polymer content ~0.5% to ~1.2% Use a different suspending mechanism (e.g., non-carboxy-vinyl crosslinked polymers, HPMC/CMC systems with different swellability/insolubility behavior, or particulate suspensions without the defined polymer parameters). Depot/sustained-release design-around Make depot release shorter than ~12 hours or avoid maintaining concentration above MIC50 for that duration. Route and indication strategy If the patent is asserted narrowly on ocular delivery, route changes (where label supports it) can reduce exposure, though that does not typically avoid all claims because the independent Claim 1 is not ophthalmic and the method claims can still be asserted with different delivery routes. What patent estate is likely implicated beyond US 7,056,893? (how this claim set maps to common families) US 7,056,893 is a formulation-centric patent that usually arises from a family with: drug-formulation dependents (pH window, polymer composition, polymer content) reconstitution/dry form dependents method of manufacture dependents (acid solubilization then neutralization) depot/sustained-release or viscosity-trigger dependents treatment method dependents (eye, topical/injection, dosing regimen) Scope linkage: the claim text is dense and repetitive across composition, method of preparation, and method of treatment. That pattern is consistent with an estate built for multi-assertion leverage: composition for product infringement, process for manufacturing infringement, and use for clinician/label scenarios. Business implication: in negotiations, the “core licensing unit” tends to be the polymer system + pH + sustained-release performance for the depot ophthalmic context. What is the Orange Book status of US 7,056,893, and how does it affect generic entry risk? Cannot be provided from the information supplied. The requested analysis requires the specific FDA application (NDA/BLA/ANDA), listed active ingredient(s), dosage form, and Orange Book patent listing entries tied to US 7,056,893. Without that mapping, an Orange Book exclusivity and Paragraph IV entry-risk assessment cannot be produced accurately. When does US 7,056,893 lose exclusivity? (expiration and enforcement timeline) Cannot be provided from the information supplied. A defensible exclusivity timeline requires the patent’s: filing date and priority chain prosecution history affecting term adjustments maintenance fee status any terminal disclaimers or patent term adjustments related exclusivity periods for the underlying FDA application What patent litigation typically arises with composition and method-of-use claims like these? Cannot be provided without the litigation docket history for US 7,056,893 and its family members, including: case captions and jurisdictions asserted claims settlement terms (noninfringement, licenses, carveouts, launch delays) FDA timing tied to ANDA/BLA challenges How strong is the claim set legally? (claim construction pressure points) Even without file-history, the claim text points to specific strength and vulnerability themes. Strength points Specific parameterization: pH ranges, polymer monomer fraction, crosslinker range, polymer loading, and depot MIC50 time window create objective boundaries. Multiple claim types: composition + method of preparation + treatment method increases assertion surface. Depot performance threshold: “above MIC50 for at least about 12 hours” can anchor functional proof, not just formulation appearance. Vulnerability points Scope dependence on polymer definition: if an accused product uses a different polymer system, infringement can fall away quickly on dependent claims (3–4). Functional performance proof: depot MIC50 duration claims can become evidentiary battlegrounds (how MIC50 is determined for a given organism, test strain, and in vivo correlate). Method-of-use route/dosing: if clinical practice or labeling deviates, treatment method subclaims may be harder to assert. Claim-by-claim map: what each independent/dependent block covers Composition block Claim 1: water + polymeric suspending agent + azalide antibiotic; pH 6.0–6.6 Claim 2: ophthalmic Claim 3–4: defined water-swellable, water-insoluble crosslinked carboxy-vinyl polymer with specified monomer/crosslinker and polymer load Claim 5–6: depot + MIC50 above for ≥12 hours Claims 7–8: azalide = azithromycin and formula constraints Claims 9–12: azithromycin concentration and narrower pH bands (6.0–6.5, 6.2–6.4, 6.3) Claims 13–14: multi-agent composition with buffering/osmolarity/EDTA and extensive “additional medicament” list Claims 15–16: dry/reconstitutable products yielding aqueous pH 6.0–6.6 Claims 37–38: additional agents list and azithromycin concentration band (0.1–0.5%) Manufacturing block Claims 17–19: acid dispersion/solubilization (pH<5) then base addition then water addition then neutralization to pH 6.0–6.6 Claim 20: ocular viscosity increase on pH rise to ≥7.0 Claim 21–22: depot sustained-release (≥12 hours) and optional osmolarity adjustment Treatment block Claims 23–26: bacterial infection treatment generally at pH 6.0–6.6 with regimen subranges Claims 27–33: ocular route, injection/topical; depot sustained release; azithromycin-specific Claims 34–35: osmolarity agent and additional medicaments Claims 39–44: dosing regimen timing ranges for general and ocular treatments Key Takeaways US 7,056,893 is built around a tight formulation triangle: pH ~6.0–6.6, azalide antibiotic (often azithromycin), and a defined crosslinked carboxy-vinyl polymer suspending system. Ophthalmic and depot coverage are present through dependent claims; depot includes a performance threshold of sustained exposure above MIC50 for ≥~12 hours. The estate includes composition, manufacturing method, and treatment method claims, which can widen enforcement reach across product manufacture, formulation preparation, and clinician use patterns. For freedom-to-operate, the highest-risk overlaps are matching the pH window, using a polymer system meeting the acrylic acid monomer and crosslinker specifications, and achieving the depot sustained release duration/performance. FAQs Do the claims require azithromycin specifically, or do they cover other azalides? The broad composition claims cover “azalide antibiotic,” while azithromycin is explicitly required in dependent claims (e.g., Claims 7, 32–33). Is the patent limited to ophthalmic use only? No. Ophthalmic treatment/compositions are covered via dependent claims, but the broad composition claim itself is not limited to ophthalmic use. Can a dry powder product avoid the patent if it’s reconstituted in clinic? No. The patent includes solid/powder/lyophilized compositions that yield the claimed aqueous pH 6.0–6.6 upon water addition (Claim 15). What is the most direct design-around lever: pH or polymer? Either can work depending on infringement theory, but dependent claims (polymer specificity) make the polymer profile a major gate, while the repeated pH limitations create a clear numerical fence. How do the depot and MIC50 limitations affect infringement risk? They shift the dispute toward measurable sustained-release performance, including how long drug levels remain above MIC50 for relevant organisms under the conditions tested. References (APA) United States Patent No. 7,056,893. (Patent claims text provided in prompt). More… ↓ ⤷ Start Trial

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	296093	⤷ Start Trial
Australia	2002322002	⤷ Start Trial
Australia	3920300	⤷ Start Trial
Australia	772228	⤷ Start Trial
Canada	2368637	⤷ Start Trial
Canada	2445408	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,056,893

Summary for Patent: 7,056,893